Skip to main content
SpringerLink
Log in

Multimodality Imaging for Hypertrophic Cardiomyopathy

  • Imaging (Q Truong, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

Hypertrophic cardiomyopathy, an inherited autosomal dominant disease, is the most common familial cardiovascular disorder and presents with heterogeneous pathobiological, clinical, and phenotypic features. This review will explore how multimodality cardiovascular imaging offers insight into understanding and identifying these heterogeneous features which are important to reliably diagnose and risk stratify patients with HCM.

Recent findings

Beyond the left ventricular (LV) hypertrophy, multimodality imaging is able to fully characterize a number of structural and functional abnormalities seen in HCM such as mitral valve leaflet elongation, abnormal chordal attachment, accessory apical-basal muscle bundle, papillary muscle abnormalities, LV outflow tract (LVOT) obstruction, microvascular dysfunction, and fibrosis. These anatomical and functional abnormalities contribute to the spectrum of different HCM presentations. Recent research shows that various morphological subtypes of HCM present with distinct clinical, genetic, LVOT, and fibrosis characteristics. Late gadolinium enhancement as assessed by cardiac magnetic resonance imaging (CMR) is useful in risk stratification of patients with HCM. In addition, native T1 and extracellular volume may add to prognostication. Strain, as measured by echocardiography and CMR, and novel techniques, such as positron emission tomography, have shown promise in determining prognosis in HCM. Computed tomography evaluates not only for obstructive coronary artery disease, but also for variations in coronary anatomy.

Summary

Complimentary use of these imaging modalities is crucial in comprehensive evaluation of HCM as well as in diagnosing various features of HCM, differentiating it from other cardiomyopathies, and in identifying prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. Oxford Academic. 2014;35:2733–79.

    Article  PubMed  Google Scholar 

  2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–60.

    Article  CAS  PubMed  Google Scholar 

  3. Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC: Heart Failure. 2018;6:364–75.

    PubMed  Google Scholar 

  4. Antunes M de O, Scudeler TL. Hypertrophic cardiomyopathy. IJC Heart Vasc. 2020;27:100503.

    Article  Google Scholar 

  5. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73:1978–86.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Baxi AJ, Restrepo CS, Vargas D, Marmol-Velez A, Ocazionez D, Murillo H. Hypertrophic Cardiomyopathy from A to Z: Genetics, pathophysiology, imaging, and management. radiographics. Radiol Soc N Am. 2016;36:335–54.

    Google Scholar 

  7. Maron BJ, Maron MS. The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from M-mode echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9:858–72.

    Article  PubMed  Google Scholar 

  8. •• Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019;74:2333–45. The largest systematic, prospective Hypertrophic Cardiomyopathy Registry of 2755 patients utilized CMR, genetic and biomarker data to improve risk prediction in HCM and found 2 distinct subgroups with different characteristics in LV morphology, fibrosis, LVOT obstruction and sarcomere gene mutation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. •• Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic Cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69:761–73. Large retrospective study of 1940 consecutive HCM patients identified that 4.8% of this cohort had LV apical aneurysm and this subgroup had high risk for arrhythmic sudden death and thromboembolic events.

    Article  PubMed  Google Scholar 

  10. Urbano-Moral JA, Gutierrez-Garcia-Moreno L, Rodriguez-Palomares JF, Matabuena-Gomez-Limon J, Niella N, Maldonado G, et al. Structural abnormalities in hypertrophic cardiomyopathy beyond left ventricular hypertrophy by multimodality imaging evaluation. Echocardiography. 2019;36:1241–52.

    Article  PubMed  Google Scholar 

  11. Chung H, Kim Y, Park C-H, Kim J-Y, Min P-K, Yoon YW, et al. Genetic relevance and determinants of mitral leaflet size in hypertrophic cardiomyopathy. Cardiovasc Ultrasound [Internet]. 2019;17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819388/. Accessed 27 May 2020.

  12. Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy. Circulation: Cardiovascular Imaging [Internet]. Lippincott Williams & Wilkins; 2015. Available from: https://www.ahajournals.org/doi/abs/10.1161/circimaging.115.003132. Accessed 27 May 2020.

  13. Rowin EJ, Maron BJ, Lesser JR, Rastegar H, Maron MS. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. Am J Cardiol. 2013;111:1677–9.

    Article  PubMed  Google Scholar 

  14. Rajiah P, Fulton NL, Bolen M. Magnetic resonance imaging of the papillary muscles of the left ventricle: normal anatomy, variants, and abnormalities. Insights Imaging [Internet]. 2019;10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702502/. Accessed 27 May 2020.

  15. Arow Z, Nassar M, Monakier D, Assali A, Vaknin-Assa H, Kornowski R, et al. Prevalence and morphology of myocardial crypts in normal and hypertrophied myocardium by computed tomography. Int J Card Imaging. 2019;35:1347–55.

    Article  Google Scholar 

  16. Child N, Muhr T, Sammut E, Dabir D, Ucar EA, Bueser T, et al. Prevalence of myocardial crypts in a large retrospective cohort study by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:66.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sigvardsen PE, Pham MHC, Kühl JT, Fuchs A, Afzal S, Møgelvang R, et al. Left ventricular myocardial crypts: morphological patterns and prognostic implications. Eur Heart J - Cardiovasc Imaging [Internet]. 2020 [cited 2020 Jul 2]; Available from: https://doi.org/10.1093/ehjci/jeaa020

  18. • Waseem H, Adaya W-S, Helene H, Arnon A, Harry R, Chan Raymond H. Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy. Circulation: Cardiovascular Imaging American Heart Association. 2017;10:e006309. This study of 195 patients with HCM who underwent TTE and CMR imaging showed that there is discordance in measurement of LV wall thickness because of limitations in TTE technique. Accurate measurement of LVWT is important as it impacts diagnosis and prognosis.

    Google Scholar 

  19. Avegliano GP, Costabel JP, Asch FM, Sciancalepore A, Kuschnir P, Huguet M, et al. Utility of real time 3D echocardiography for the assessment of left ventricular mass in patients with hypertrophic cardiomyopathy: Comparison with Cardiac Magnetic Resonance. Echocardiography. 2016;33:431–6.

    Article  PubMed  Google Scholar 

  20. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. Elsevier. 2016;29:277–314.

    Article  PubMed  Google Scholar 

  21. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. American Society of Echocardiography Clinical Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. Elsevier. 2011;24:473–98.

    Article  PubMed  Google Scholar 

  22. Dimitrow PP, Rajtar-Salwa R. Obstructive form of hypertrophic cardiomyopathy-left ventricular outflow tract gradient: novel methods of provocation, monitoring of biomarkers, and recent advances in the treatment [Internet]. BioMed Res Int. Hindawi; 2016 [cited 2020 Jun 21]. p. e1575130. Available from: https://www.hindawi.com/journals/bmri/2016/1575130/

  23. Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y, et al. Cardiac MR imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci. 2018;17:120–31.

    Article  PubMed  PubMed Central  Google Scholar 

  24. • Hughes Rebecca K, Knott KD, James M, Augusto João B, Mohiddin Saidi A, Peter K, et al. Apical hypertrophic cardiomyopathy: the variant less known. Journal of the American Heart Association. American Heart Association. 2020;9:e015294. This is a comprehensive updated review on epidemiology, clinical expression, genetics, multimodality imaging, management strategies and prognosis of apical HCM as well as highlights knowledge gaps.

    Article  CAS  Google Scholar 

  25. Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, et al. Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete’s heart. J Am Coll Cardiol. 2016;67:2189–90.

    Article  PubMed  Google Scholar 

  26. Neisius U, El-Rewaidy H, Nakamori S, Rodriguez J, Manning WJ, Nezafat R. Radiomic Analysis of myocardial native T1 imaging discriminates between hypertensive heart disease and hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2019;12:1946–54.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Mayala HA, Bakari KH, Zhaohui W. The role of cardiac magnetic resonance (CMR) in the diagnosis of cardiomyopathy: a systematic review. Malawi Med J. 2019;31:241–5.

    PubMed  PubMed Central  Google Scholar 

  28. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–8.

    Article  PubMed  Google Scholar 

  29. Minegishi S, Kato S, Takase-Minegishi K, Horita N, Azushima K, Wakui H, et al. Native T1 time and extracellular volume fraction in differentiation of normal myocardium from non-ischemic dilated and hypertrophic cardiomyopathy myocardium: a systematic review and meta-analysis. Int J Cardiol Heart Vasc [Internet]. 2019 [cited 2020 Jul 2];25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737306/

  30. • Bois JP, Geske JB, Foley TA, Ommen SR, Pellikka PA. Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography. Am J Cardiol. 2017;119:643–50. Retrospective study of 618 patients with HCM who underwent TTE and CMR imaging showed that LV wall thickness measurement was identical between the two imaging modalities in only 12% of patients highlighting the discrepancy between the techniques for maximal LV wall thickness representing real world findings (as opposed to standardized measurements).

    Article  PubMed  Google Scholar 

  31. Rodriguez-Granillo GA, Deviggiano A, Capunay C, Zan MCD, Carrascosa P, Rodriguez-Granillo GA, et al. Reproducibility of gadolinium enhancement patterns and wall thickness in hypertrophic cardiomyopathy. Arquivos Brasileiros de Cardiologia Arquivos Brasileiros de Cardiologia. 2016;107:48–54.

    PubMed  Google Scholar 

  32. Chan RH, Maron BJ, Iacopo O, Pencina Michael J, Egidy AG, Tammy H, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. Am Heart Assoc. 2014;130:484–95.

    Google Scholar 

  33. • Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late Gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72:857–70. Observational study of 1423 consecutive low and intermediate risk patients with HCM and with preserved LVEF who underwent TTE and CMR imaging showed incremental prognostic utility of LGE. LGE ≥ 15% was associated with increased risk of SCD and appropriate ICD discharge.

    Article  PubMed  Google Scholar 

  34. Weissler-Snir A, Hindieh W, Spears DA, Adler A, Rakowski H, Chan RH. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: a delayed contrast-enhanced magnetic resonance study. J Cardiovasc Electrophysiol. 2019;30:651–7.

    Article  PubMed  Google Scholar 

  35. Freitas P, Ferreira AM, Arteaga-Fernández E, de Oliveira Antunes M, Mesquita J, Abecasis J, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson [Internet]. 2019 [cited 2020 Jun 4];21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694533/

  36. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–7.

    Article  PubMed  Google Scholar 

  37. Weng Z, Chan RH, Yao J, Zhou Y, He Y. Prognostic value of late gadolinium enhancement cardiac magnetic resonance in hypertrophic cardiomyopathy: a meta-analysis. J Cardiovasc Magn Reson. 2016;18:P117.

    Article  PubMed Central  Google Scholar 

  38. • Todiere G, Nugara C, Gentile G, Negri F, Bianco F, Falletta C, et al. Prognostic role of late gadolinium enhancement in patients with hypertrophic cardiomyopathy and low-to-intermediate sudden cardiac death risk score. Am J Cardiol. 2019;124:1286–92. Multicenter study of 354 consecutive HCM patients with a low to intermediate 5-year ESC SCD score who underwent CMR showed that LGE extent was the best independent predictor of hard cardiac events. The estimated 5-year risk of hard cardiac events was 2.5% in patients with LGE < 10% and 23.4% in patients with LGE > 10%.

    Article  CAS  PubMed  Google Scholar 

  39. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J Oxford Academic. 2014;35:2010–20.

    Article  Google Scholar 

  40. • O’Mahony C, Fatima J, Ommen Steve R, Imke C, Eloisa A, Pablo G-P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation Am Heart Assoc. 2018;137:1015–23. Large, international, multicenter, observational, retrospective, longitudinal cohort study of 3703 HCM patients designed to validate the 2014 ESC guidelines on SCD prevention showed that these guidelines differentiate high from low risk patients reasonably well.

    Google Scholar 

  41. • Leong KMW, Chow J-J, Ng FS, Falaschetti E, Qureshi N, Koa-Wing M, et al. Comparison of the prognostic usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;121:349–55. Retrospective study of 288 HCM patients compared ESC risk scoring system to ACCF/AHA guidelines and concluded that per current ESC scoring system, more high risk patients would’ve not met criteria for an ICD in this cohort of patients.

    Article  PubMed  PubMed Central  Google Scholar 

  42. •• Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, et al. Enhanced American College of Cardiology/American Heart Association Strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:644–57. Large, observational longitudinal study of 2094 HCM patients who underwent prospective ICD decision making based on individual risk markers per the HCM literature and enhanced ACC/AHA guidelines-based risk factor algorithm found that this strategy predicted SCD events in nearly all-at risk patients. When this strategy was compared with the ESC risk score applied retrospectively, it was found that ESC score was less sensitive and recognized fewer high risk patients.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Kato S, Nakamori S, Bellm S, Jang J, Basha T, Maron M, et al. Myocardial native T1 time in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;118:1057–62.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Huang L, Ran L, Zhao P, Tang D, Han R, Ai T, et al. MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy: tissue remodeling manifested prior to structure changes. BJR Br Instit Radiol. 2019;92:20190634.

    Article  Google Scholar 

  45. Xu J, Zhuang B, Sirajuddin A, Li S, Huang J, Yin G, et al. MRI T1 mapping in hypertrophic cardiomyopathy: evaluation in patients without late gadolinium enhancement and hemodynamic obstruction. Radiology. Radiol Soc N Am. 2019;294:275–86.

    Google Scholar 

  46. • Liu JM, Liu A, Leal J, McMillan F, Francis J, Greiser A, et al. Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects. J Cardiovasc Magn Reson. 2017;19:74. This study of 1291 subjects provides typical T1-ranges at 1.5 T CMR for normal values as well as different clinical cardiac conditions (HTN, Afib, aortic stenosis) and cardiomyopathies (HCM, amyloidosis, sarcoidosis, dilated cardiomyopathy, etc.)

    Article  PubMed  PubMed Central  Google Scholar 

  47. Rosmini S, Bulluck H, Treibel TA, Abdel-Gadir A, Bhuva AN, Culotta V, et al. Native myocardial T1 and ECV with age and gender developing normal reference ranges - a 94 healthy volunteer study. J Cardiovasc Magn Reson. 2016;18:O42.

    Article  PubMed Central  Google Scholar 

  48. • Shin YJ, Lee JH, Yoo JY, Kim JA, Jeon Y, Yoon YE, et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29:4593–602. Retrospective study of 238 patients with HCM who underwent coronary CTA for chest pain showed that coronary CTA has incremental prognostic value to clinical and TTE variables for predicting adverse cardiac events.

    Article  PubMed  Google Scholar 

  49. Nassar M, Arow Z, Monakier D, Zusman O, Shafir G, Kornowski R, et al. Effect of intramural course of coronary arteries assessed by computed tomography angiography in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2019;124:1279–85.

    Article  PubMed  Google Scholar 

  50. Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Cardiol. 2018;25:269–97.

    Article  PubMed  Google Scholar 

  51. Olivotto I, Girolami F, Sciagrà R, Ackerman MJ, Sotgia B, Bos JM, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011;58:839–48.

    Article  PubMed  Google Scholar 

  52. Magnusson P, Nordström J, Harms HJ, Lubberink M, Gadler F, Sörensen J, et al. Positron emission tomography (15O-water, 11C-acetate, 11C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc [Internet]. 2019 [cited 2020 Jun 21];26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046493/

  53. Lu D-Y, Yalçin H, Yalçin F, Zhao M, Sivalokanathan S, Valenta I, et al. Stress myocardial blood flow heterogeneity is a positron emission tomography biomarker of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121:1081–9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Mirea O, Pagourelias ED, Duchenne J, Bogaert J, Thomas JD, Badano LP, et al. Variability and reproducibility of segmental longitudinal strain measurement: a report from the EACVI-ASE Strain Standardization Task Force. JACC Cardiovasc Imaging. 2018;11:15–24.

    Article  PubMed  Google Scholar 

  55. Satriano A, Heydari B, Guron N, Fenwick K, Cheung M, Mikami Y, et al. 3-Dimensional regional and global strain abnormalities in hypertrophic cardiomyopathy. Int J Card Imaging. 2019;35:1913–24.

    Article  Google Scholar 

  56. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100:1673–80.

    Article  PubMed  Google Scholar 

  57. Zhao X, Tan RS, Tang HC, Leng S, Zhang J-M, Zhong L. Analysis of three-dimensional endocardial and epicardial strains from cardiac magnetic resonance in healthy subjects and patients with hypertrophic cardiomyopathy. Med Biol Eng Comput. 2018;56:159–72.

    Article  PubMed  Google Scholar 

  58. Neisius U, Myerson L, Fahmy AS, Nakamori S, El-Rewaidy H, Joshi G, et al. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS One. 2019;14:e0221061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pagourelias ED, Mirea O, Vovas G, Duchenne J, Michalski B, Van Cleemput J, et al. Relation of regional myocardial structure and function in hypertrophic cardiomyopathy and amyloidois: a combined two-dimensional speckle tracking and cardiovascular magnetic resonance analysis. Eur Heart J Cardiovasc Imaging. 2019;20:426–37.

    Article  PubMed  Google Scholar 

  60. Tower-Rader A, Mohananey D, To A, Lever HM, Popovic ZB, Desai MY. Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature. JACC Cardiovasc Imaging. 2019;12:1930–42.

    Article  PubMed  Google Scholar 

  61. Huang L, Que. L, Xi Y, Zhuang J, Yuan H, Liu H, et al. Myocardial mechanics parameters that predict left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance feature tracking analysis. J Comp Assisted Tomogr [Internet]. 2020 [cited 2020 Jun 20]; Publish Ahead of Print. Available from: https://journals.lww.com/jcat/Abstract/9000/Myocardial_Mechanics_Parameters_That_Predict_Left.99045.aspx

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA

    Elona Rrapo Kaso MD & Christopher M. Kramer MD

  2. Department of Radiology, University of Virginia Health System, Charlottesville, VA, USA

    Christopher M. Kramer MD

Authors
  1. Elona Rrapo Kaso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher M. Kramer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher M. Kramer MD.

Ethics declarations

Conflict of Interest

Dr. Kramer reports grants from Cytokinetics, outside the submitted work. In addition, Dr. Kramer has a patent 16/295,939 pending. Elona Rrapo Kaso declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Imaging

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rrapo Kaso, E., Kramer, C.M. Multimodality Imaging for Hypertrophic Cardiomyopathy. Curr Treat Options Cardio Med 22, 26 (2020). https://doi.org/10.1007/s11936-020-00827-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-020-00827-9

Keywords

Search

Navigation